Maravai LifeSciences $1 billion secondary offering
The shares are listed on the Nasdaq Global Select Market
Davis Polk advised the joint book-running managers in connection with the $1 billion secondary offering of 20,000,000 shares of Class A common stock of Maravai LifeSciences Holdings, Inc. by certain selling shareholders. Maravai’s Class A common stock is listed on the Nasdaq Global Select Market under the symbol “MRVI.”
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. Maravai’s products address the key phases of biopharmaceutical development and include complex nucleic acids for diagnostic and therapeutic applications and biologic safety testing. Maravai LifeSciences is headquartered in San Diego, California.
The Davis Polk corporate team included partner Alan F. Denenberg and counsel Jeffrey Gould. Partner Mario J. Verdolini and associate Benjamin Helfgott provided tax advice. Partner David R. Bauer and associate Marisa Elena Bannon provided intellectual property advice. Counsel Sarah E. Kim and associate Alisan Oliver-Li provided ‘40 Act advice. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.